ACADIA Pharmaceuticals Inc. (ACAD) Q2 FY26 Earnings Call

Strong Daybue execution and an upcoming Remlafanserin readout are the call's principal growth signals.

Q2 FY26 results, source: company transcript and SEC filings
QuarterQ2 FY26
Length63 minutes
EPS$0.18

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

Other quarters: Q1 FY26 · Q4 FY25

All ACAD earnings · Back to ACAD overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.